Impact Biomedical Q2 FY26: revenue $3K, down 57%; diluted EPS −$0.01
Impact Biomedical (IBO) filed a 10-Q with the SEC on Aug 7, 2026, 4:32 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001493152-26-036601
Key figures from this report
These are the numbers Impact Biomedical reported for Q2 FY26, the quarter ended Jun 30, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$3K−57% from $7K in Q2 FY2510-Q income statement, on EDGAR
- Net income−$699KAgainst −$14.3M in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$0.01Against −$1.18 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$10K−98% from $624K in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations$470KAgainst −$694K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters